Roche Shares Jump Following Successful Studies for Two Drugs
- Tecentriq delays worsening of lung tumors in combination
- Rivals Merck, Bristol-Myers see shares fall on study news
This article is for subscribers only.
Roche Holding AG shares surged after two experimental medicines for cancer and hemophilia succeeded in much-anticipated patient trials, boding well for the Swiss drugmaker’s ability to grow as its biggest drugs face competition.
A cancer treatment called Tecentriq delayed the worsening of lung tumors when given together with chemotherapy and an older Roche medicine, Avastin. Meanwhile, a drug known as Hemlibra succeeded in a late-stage study of the biggest group of hemophilia A patients, putting the company in a position to shake up the $10 billion global market for treating the blood disorder.